Table 6.
Cost Effectiveness of MDR LTBI Treatment Regimens: Scenario of Low (Lower CI level) for AE Discontinuation and High (4.4%) TB Incidence
| Estimated regimen efficacy | Estimated % stop due to AE | Estimated % completion | Estimated U.S. MDR TB cases over 40 remaining years of life | TB cases prevented | Discounted cases prevented | Remaining Lifetime QALYs | Estimated regimen cost | Discounted Net Cost (Program Cost-Cost of TB Cases Prevented) | Incremental Cost (Saving) per Case Prevented | |
|---|---|---|---|---|---|---|---|---|---|---|
| % | % | % | # | # | # | 2014$ | 2014$ | 2014$ | ||
| No Tx | 704 | 0 | – | 23.6858 | $ 16,469,760 | |||||
| PZA/FQ | 90% | 57% | 40% | 451 | 253 | 146 | 23.6380 | $ 1,993 | $ (13,716,976) | saving |
| FQ alone | 62% | 2% | 87% | 324 | 380 | 219 | 23.6935 | $ 1,461 | $ (28,104,187) | saving |
| PZA/EMB | 62% | 11% | 89% | 316 | 388 | 224 | 23.6852 | $ 1,350 | $ (30,579,993) | saving |
| FQ/EMB | 76% | 0% | 80% | 276 | 428 | 247 | 23.6966 | $ 1,893 | $ (29,498,490) | saving |
| FQ/ETA | 69% | 0% | 100% | 218 | 486 | 281 | 23.6981 | $ 4,213 | $ 4,133,156 | not cost effective |